Literature DB >> 823381

Considerations in the development of artificial heart valve substitutes for use in infants in small children.

N S Braunwald, M Brais, A Castaneda.   

Abstract

Experimental studies carried out in our laboratory suggest that it is possible to develop a family of stent-supported tissue valve substitutes suitable for use in tissue and annuli of the hearts of small children in tissue annulus sizes ranging from 12 to 22 mm. Either glutaraldehyde-preserved, stent-supported primate tissue aortic valves or tissue leaflet valves constructed from dura mater preserved in 98 per cent glycerine can be used. In both instances, hemodynamics assessment of the valve substitutes in a mock circulation indicated that function was acceptable at the cardiac outputs normal for infants and children during the first few years of life. Stent-supported dura mater valves 16 nm. in diameter have been used to replace the mitral valve in 2 infants 7 and 8 months of age with complete atrioventricular canal defects and mitral regurgitation, one of whom survives with demonstratable satisfactory hemodynamic function of the valve substitute.

Entities:  

Mesh:

Year:  1976        PMID: 823381

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Valve replacement in children.

Authors:  M J Elliott; M de Leval
Journal:  World J Surg       Date:  1985-08       Impact factor: 3.352

2.  Mitral valve replacement in the neonate: a report of two cases.

Authors:  W J Duncan; B Bharadwaj; M J Tyrrell
Journal:  Pediatr Cardiol       Date:  1984       Impact factor: 1.655

3.  Premeditated reoperation after mitral valve replacement with a Starr-Edwards ball valve for young women who desire to bear a child: report of two cases.

Authors:  Ryota Asano; Kiyoharu Nakano; Kojiro Kodera; Noriyuki Murai; Akihito Sasaki; Masahiro Ikeda; Go Kataoka; Akiko Yamaguchi; Satoru Domoto; Yasuo Takeuchi
Journal:  Surg Today       Date:  2009-07-29       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.